Off the shelf stem cells, be it MPCs , MSCs or NK cells, until proven not the case , we must assume that they are all variable in affect and potency. Cost of trials is only a fraction of the over all development cost. 20 million would only be a fraction of the cost to get a off the shelf product to market . 10 to 20 times that and we might get to a point where we know the main factors that would need to have assays for and a AOK potency assay for the FDA to approve.
The way I see it , with investors refusing to pay increasing prices for tickets in biotech companies the only long term solution is consolidation of assets to form larger pools of similar products within the same company.
A for sale sign has been put on the door, what ever the deal , the long term benefit to current holders is the only concern the board should consider. The deal unfortunately would likely not represent real short term returns for those that put capital in the early days how ever I would think it should be better than what we have now in SP value.
CHM Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)